STLN · Starling Oncology, Inc. · Executive Compensation
$6.35
+0.14 (+2.17%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $41,094 and an accumulated deficit of $283,700 at June 30, 2026, and a net loss of $12,281 and net cash provided by operations of $9,725 for the six months ended June 30, 2026. The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$678.76M
Shares
101.92M
Volume · Oct 2
793.88K
Avg daily vol (3M)
1.58M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,934,930 |
| Yale Podnos | — | $775,905 |
| Robert Carter | — | $734,130 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,118,358 |
| Mihir Shah | — | $733,144 |
| Jeremy Castle | — | $622,220 |
| Yale Podnos | — | $610,332 |
| Robert Carter | — | $434,404 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $1,215,190 |
| Daniel Virnich | — | $808,129 |
| Mihir Shah | — | $801,743 |
| Yale Podnos | — | $591,284 |
| Jeremy Castle | — | $486,126 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $6,629,723 |
| Daniel Virnich | — | $3,244,461 |
| Mihir Shah | — | $2,264,237 |
| Yale Podnos | — | $1,249,186 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $11,635,536 |
| Daniel Virnich | — | $7,638,167 |
| Scott Dalgleish | — | $4,758,691 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $611,400 |
| Daniel Virnich | — | $418,684 |
| Scott Dalgleish | — | $317,583 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kimberly Tzoumakas | Director | Appointed | 2026-02-23 |
| Mark D. Stolper | Director | Appointed | 2026-01-07 |
| Gabriel Ling | Board of Directors | Resigned | 2025-12-01 |
| Anne McGeorge | Chair of the Board | Appointed | 2025-08-13 |
| Richard Barasch | Chairman of the Board | Resigned | 2025-08-13 |
| Jeremy Castle | Chief Operating Officer | Resigned | 2025-05-07 |
| Maeve O'Meara | director | Resigned | 2024-11-12 |
| Robert Carter | Chief Financial Officer | Appointed | 2024-09-23 |
| Robert Carter | principal accounting officer | Appointed | 2024-09-23 |
| Mihir Shah | principal accounting officer | Resigned | 2024-09-23 |
| Mihir Shah | Chief Financial Officer | Resigned | 2024-09-23 |
| Jeremy N. Castle | Chief Operations Officer | Appointed | 2023-09-06 |
| Ravi Sarin | director of the Board | Resigned | 2023-09-01 |
| Daniel Virnich | Chief Executive Officer | Appointed | 2023-06-12 |
| Brad Hively | Chief Executive Officer | Resigned | 2023-06-12 |
| Matthew Miller, M.D. | Chief Operating Officer | Terminated | 2023-05-22 |
| Diona Simoneit | Chief Accounting Officer and principal accounting officer | Resigned | 2022-12-01 |
| Gabriel Ling | Board | Appointed | 2022-09-22 |
| Mark Pacala | Board | Appointed | 2022-09-22 |